Printer Friendly

DAVSTAR INDUSTRIES ANTICIPATES MEDICARE COVERAGE OF DRISTAR SYSTEM

DAVSTAR INDUSTRIES ANTICIPATES MEDICARE COVERAGE OF DRISTAR SYSTEM
    NEWPORT BEACH, Calif., July 8 /PRNewswire/ -- Davstar Industries Ltd. (AMEX: DVS) announced today that it anticipates Medicare coverage for a new, proprietary product that could replace adult diapers for patients with permanent urinary incontinence.
    Davstar is seeking approval for its DriStar(TM) system, which Davstar believes would become the lone entrant of its kind in a $3.2 billion market for urinary incontinence products.  The product is targeted to females in nursing homes and bedridden patients cared for at home.  DriStar consists of an absorbent pad, similar to a sanitary napkin, connected via a tube to a silent, battery-operated pump.  Constant air flow keeps the patient dry, free of irritation and odor.
    "We anticipate that Medicare will reimburse patient costs of the DriStar system, based on correspondence we have received from the Department of Health and Human Services, which states that our system may fall within existing coverage guidelines for patients with permanent urinary incontinence," said Jerry B. Silver, president and chief executive officer of Davstar.  "This would be a major step for incontinent patients in America.  DriStar has the benefit of not only providing comfort and dignity for our aging population, but also of significantly lowering health care costs."
    About 2 million non-ambulatory people in U.S. nursing homes are currently treated for urinary incontinence.  Estimates place the total number of Americans suffering from the problem to be as high as 12 million, with the number likely to increase dramatically as the population ages.  DriStar would provide an alternative to adult diapers, which are more expensive when staff time and materials are included.
    Davstar has also filed its 510(k) pre-market notification with the Food and Drug Administration.  In 1989, the FDA granted Davstar approval within 90 days for an earlier non-invasive product, a plastic centrifuge tube called CenSlide(R).
    "Once we have the necessary approvals, we anticipate bringing DriStar to market before the end of 1992," said Silver.  "We have completed the plastic molding and production models for the system, and have ordered production equipment."
    Davstar develops and markets proprietary, non-invasive medical and laboratory products, and manufactures molded plastic products and components for commercial, industrial and consumer applications.
    Direct all inquiries to Roberta Stauffer, c/o Davstar Industries Ltd., One Newport Place, 1301 Dove St., Suite 360, Newport Beach, CA 92660 or call 714-842-8492.
    -0-                    7/8/92
    /CONTACT:  Roberta Stauffer of Davstar, 714-842-8492/
    (DVS) CO:  Davstar Industries Ltd. ST:  California IN:  MTC SU: AL-CH -- LA020 -- 7494 07/08/92 14:29 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 8, 1992
Words:423
Previous Article:SONY AND SPRINT TELL CONSUMERS 'IT'S TIME TO TALK'; CONSUMERS CAN RECEIVE UP TO TWO HOURS OF FREE LONG DISTANCE CALLING FROM SPRINT
Next Article:BI ANNOUNCES OVER $2 MILLION IN RECENT NEW ORDERS
Topics:


Related Articles
DAVSTAR INDUSTRIES PUBLIC OFFERING OF UNITS DECLARED EFFECTIVE BY SEC
DAVSTAR UPDATES STATUS OF DRISTAR(TM) AND CENSLIDE(R) PRODUCTS
POTENTIAL MEDICARE REIMBURSEMENT FOR DAVSTAR'S INCONTINENT SYSTEM
DAVSTAR BEGINS FULL-SCALE PRODUCTION AND INITIAL DISTRIBUTION OF REVOLUTIONARY PATENTED CEN-SLIDE(R) URINALYSIS SYSTEM
DAVSTAR FILES FOR PATENT ON CEN-SLIDE(R) COLLECTOR CUP
UNIVERSITY TARGETS DAVSTAR'S CEN-SLIDE(R) FOR DRUG ABUSE TESTING; $500 MILLION ANNUAL MARKET TO GROW $900 MILLION BY 1995
DAVSTAR SUPPORTS FDA HIGHER CLINICAL STANDARDS
DAVSTAR FILES 510(k) DOCUMENTATION WITH FDA ON DRISTAR(R)
DAVSTAR RECEIVES FDA 510(k) NOTIFICATION CLEARANCE FOR DRISTAR(R)
DAVSTAR OBTAINS FUNDING FOR INITIAL DRISTAR MARKETING PROGRAM

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters